Pharmacokinetics, Pharmacodynamics Profile and Tolerance of HRS-9231 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 5, 2024

Primary Completion Date

October 6, 2024

Study Completion Date

October 6, 2024

Conditions

Healthy Volunteers

Interventions

DRUG

HRS-9231

HRS-9231 was administered intravenously;

DRUG

Placebo

Placebo was administered intravenously.

Trial Locations (1)

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors

lead

Shanghai Shengdi Pharmaceutical Co., Ltd

INDUSTRY

NCT07123376 - Pharmacokinetics, Pharmacodynamics Profile and Tolerance of HRS-9231 in Healthy Subjects | Biotech Hunter | Biotech Hunter